Dipeptidyl Peptidase-4 Inhibitors, a New Option for the Management of Type 2 Diabetes Mellitus

Autor:	Bogdan Timar, Laura Diaconu, Oana Albai, Romulus Timar
Rok vydání:	2012
Předmět:	medicine.medical_specialty medicine.diagnostic_test business.industry Type 2 Diabetes Mellitus Type 2 diabetes medicine.disease Metformin Endocrinology Oral administration Internal medicine Sitagliptin medicine Lipid profile business Dipeptidyl peptidase-4 Glycemic medicine.drug
Zdroj:	Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 19:343-351
ISSN:	2284-6417 2068-8245
DOI:	10.2478/v10255-012-0040-2
Popis:	Objective: Despite the diversity of antidiabetic medication currently available, lessthan half of the patients with type 2 diabetes meet the therapeutic targetsrecommended by the guidelines: HbA1c investigate the efficacy and safety of sitagliptin in patients with type 2 diabetesmellitus, with inadequate glycemic control, as well as the effects on cardiovascularrisk factors. Material and method: The study included 348 patients, 161 men(46.3%) and 187 women (53.7%), with mean age of 56.1 ± 6.2 years, who startedtreatment with sitagliptin, combined with either metformin, sulphonylurea or both.Results and discussions: Sitagliptin improved glycemic control reducing averageHbA1c with 1.1%; the average weight decreased with 1.7 kg after 24 weeks oftreatment, and the lipid profile improved significantly. Conclusions: Sitagliptinoffers a new therapeutic option in patients with type 2 diabetes mellitus, with theadvantage of a single dose oral administration.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1f6267f94836db1788877c9b6a97daa6 https://doi.org/10.2478/v10255-012-0040-2 Zobrazit plný text záznamu